Nephropathy - Pipeline Review, H2 2015 Is Released

Nephropathy - Pipeline Review, H2 2015 Summary Global Markets Direct s, Nephropathy - Pipeline
Review, H2 2015, provides an overview of the Nephropathys therapeutic pipeline. This report provides
comprehensive information on the therapeutic development for Nephropathy, complete with
comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news
and press releases. It also reviews key players involved in the therapeutic development for Nephropathy
and special features on late-stage and discontinued projects. Global Markets Directs report features
investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The
report is built using data and information sourced from Global Markets Directs proprietary databases,
Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets
Directs team. Drug profiles/records featured in the report undergoes periodic updation following a
stringent set of processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking, browser based alert-box and
clinical trials registries tracking ensure that the most recent developments are captured on a real time
basis. The report enhances decision making capabilities and help to create effective counter strategies
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data for the indicated disease. Scope - The report
provides a snapshot of the global therapeutic landscape of Nephropathy - The report reviews key
pipeline products under drug profile section which includes, product description, MoA and R&D brief,
licensing and collaboration details & other developmental activities - The report reviews key players
involved in the therapeutics development for Nephropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects - A review of the
Nephropathy products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources - Pipeline products coverage based on
various stages of development ranging from pre-registration till discovery and undisclosed stages - A
detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the
Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest
news and deals relating related to pipeline products Reasons to buy - Provides strategically significant
competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas
of leading companies - Identify and understand important and diverse types of therapeutics under
development for Nephropathy - Plan mergers and acquisitions effectively by identifying key players of
the most promising pipeline - Devise corrective measures for pipeline projects by understanding
Nephropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and
out-licensing strategies by identifying prospective partners with the most attractive projects to enhance
and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline.

with
TOC
@
http://www.idatainsights.com/reports-landingpage.php?id=173385/nephropathy-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173385/nephropathy-pipeline-review-h2-2015

Table of Contents

Introduction 5
Global Markets Direct Report Coverage 5
Nephropathy Overview 6
Therapeutics Development 7
Pipeline Products for Nephropathy - Overview 7
Nephropathy - Therapeutics under Development by Companies 8
Nephropathy - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Nephropathy - Products under Development by Companies 12
Nephropathy - Companies Involved in Therapeutics Development 13
Anthera PharmaceuticalsInc. 13
Boehringer Ingelheim GmbH 14
ChemoCentryx, Inc. 15
Complexa, Inc. 16
Promedior, Inc. 17
Nephropathy - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
2

Assessment by Molecule Type 25

Drug Profiles 27
blisibimod - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CCX-168 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CXA-10 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
imatinib mesylate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PRM-151 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
R-801 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36

R-901 - Drug Profile 38

Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule to Inhibit Casein Kinase 2 for Cancer and Nephritis - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Nephropathy - Recent Pipeline Updates 42
Nephropathy - Dormant Projects 52
Nephropathy - Discontinued Products 53
Nephropathy - Product Development Milestones 54
Featured News & Press Releases 54
Mar 16, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial
with Blisibimod for IgA Nephropathy 54
Oct 01, 2014: Anthera Pharmaceuticals Announces Update on Strategic Partnership Discussions For
Blisibimod 54
Sep 25, 2013: Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension
Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting 54
Jun 24, 2013: Anthera Pharma Initiates BRIGHT-SC Phase II Clinical Study In IgA Nephropathy With
Blisibimod 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
4

Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173385/nephropathypipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects